XML 21 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
 6 Months Ended
Jun. 30, 2013
Segment Reporting [Abstract]  
Operating Segment And Geographic Information
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
Our chief operating decision-maker is our Chief Executive Officer, who regularly evaluates our performance based on net sales and net loss before taxes. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be directionally correct, actual results could differ from the estimates and assumptions used in preparing this information.
The accounting policies of the segments are the same as the policies discussed in Note 2 – "Summary of Significant Accounting Policies" to the notes to our accompanying unaudited condensed consolidated financial statements.
In the first quarter of 2013, we consolidated our Clinical Laboratories and Pharmacogenomic Services business segments into a single segment and, going forward, it will be referred to as our Laboratory Services segment. We now have two reportable operating segments, Laboratory Services and Diagnostic Tools. Accordingly, segment results of the prior period have been reclassified to reflect these changes.
 
Segment information for the three months ended June 30, 2013 and 2012 is as follows:
 
 
Dollars in Thousands
 
2013
 
Laboratory Services
 
Diagnostic
Tools
 
Total
Net Sales
$
4,012

 
$
3,294

 
$
7,306

Gross Profit
1,853

 
1,557

 
3,410

Net Loss before Taxes
(2,181
)
 
(692
)
 
(2,873
)
Income Tax Benefit
—

 
(6
)
 
(6
)
Net Loss
$
(2,181
)
 
$
(686
)
 
$
(2,867
)
Depreciation/Amortization
$
646

 
$
41

 
$
687

Interest Expense, net
$
84

 
$
67

 
$
151

 
 
 
 
 
 
 
June 30, 2013
Total Assets
$
27,834

 
$
11,529

 
$
39,363


 
 
 
 
 
 
 
Dollars in Thousands
 
2012
 
Laboratory Services
 
Diagnostic
Tools
 
Total
Net Sales
$
5,808

 
$
3,285

 
$
9,093

Gross Profit
3,117

 
1,445

 
4,562

Net Income (Loss) before Taxes
(624
)
 
31

 
(593
)
Income Tax Benefit
—

 
(30
)
 
(30
)
Net Income (Loss)
$
(624
)
 
$
61

 
$
(563
)
Depreciation/Amortization
$
467

 
$
65

 
$
532

Interest Expense, net
$
221

 
$
10

 
$
231

 
 
 
 
 
 
 
June 30, 2012
Total Assets
$
31,101

 
$
13,571

 
$
44,672


Segment information for the six months ended June 30, 2013 and 2012 is as follows:
 
Dollars in Thousands
 
2013
 
Laboratory Services
 
Diagnostic
Tools
 
Total
Net Sales
$
8,439

 
$
6,241

 
$
14,680

Gross Profit
4,046

 
3,045

 
7,091

Net Loss before Taxes
(5,267
)
 
(1,127
)
 
(6,394
)
Income Tax Expense
—

 
60

 
60

Net Loss
$
(5,267
)
 
$
(1,187
)
 
$
(6,454
)
Depreciation/Amortization
$
1,209

 
$
222

 
$
1,431

Interest Expense, net
$
219

 
$
85

 
$
304



 
 
 
 
 
 
 
Dollars in Thousands
 
2012
 
Laboratory Services
 
Diagnostic
Tools
 
Total
Net Sales
$
9,809

 
$
6,490

 
$
16,299

Gross Profit
4,764

 
2,902

 
7,666

Net Income (Loss) before Taxes
(2,711
)
 
(574
)
 
(3,285
)
Income Tax Benefit
—

 
(26
)
 
(26
)
Net Income (Loss)
$
(2,711
)
 
$
(548
)
 
$
(3,259
)
Depreciation/Amortization
$
915

 
$
130

 
$
1,045

Interest Expense, net
$
473

 
$
31

 
$
504


Net sales for the three and six months ended June 30, 2013 and 2012 by country were as follows:
 
 
Dollars in Thousands
 
Dollars in Thousands
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2013
 
2012
 
2013
 
2012
United States
$
5,797

 
$
6,847

 
$
11,146

 
$
11,571

Italy
372

 
907

 
827

 
1,706

All Other Countries
1,137

 
1,339

 
2,707

 
3,022

Total
$
7,306

 
$
9,093

 
$
14,680

 
$
16,299


Other than the countries specifically identified above, no other country individually accounted for more than 5% of total net sales.

More than 95% of our long-lived assets are located within the United States.